I




Fig. 1





Fig. 2






Fig. 3




Fig. 4

Α 10 20 Caf1 ADLTASTT<u>ATATLV</u>EPARITLT... Δ Caf1 ADLTASTTS----EPARITLT... В

Fig. 5

Deleted variant of Cafl	Position of deletion in the	Polymerization of Cafl in
	N-terminal extention	periplasm
d1	AD****TTA	+++
d2	¹ AD******TAT ¹²	+++
d3	ADLTASTTS****EPAR ¹⁸	-
d4	ADLTASTTS******R ¹⁸	-
d5	'ADLTASTTATATLVEP**** LTYK ²⁴	+
d6	¹ ADLTASTTATATLVEPARI* ***K ²⁴	+/-

Fig. 6




Fig. 7





Fig. 8








Fig 9.

A a non efficient drug molecule X




Fig. 10 A

B An efficient drug molecule




Fig. 10 B

Subunit Cafi	Organelle F1 capsular antigen	ADLTASTT	A T
MylA PsaA	Myi nbrilae PH6 antigen	EPTVINSKDIS	TKTVK
AggA	AAF-I		> t. - €
AafA	AAF-III		ц с
AfaE-1	AFA-I		ر م ا د
AfaE-2	AFA-II	AVDKHAT	> > J F
AfaE-3	AFA-III		7 T
DraE	Dr haemagglutinin		4 2
AfaE-5	AFA-V		4 Þ
DrbE-122	Drb122		4
DrvE-121	Drh121		I K
חסים	D10121	FQPSGTT	V E
Daar	F1845 rimbriae	FQASGTT	TT
CseA	CS22 fmbriae	V V G D V A T V Q	^ ^
CS-3	CS-3 fimbriae	AGPTLTKEL	> 2
NfaE-111	NFA	V L N G V G G A D G I R L G T A T	· E
Dra2E	Dr-II	ANGLNTVNAGDGKNLGTAT	- [-)
NfaA	NFA-I	ANGLNTVNAGORKNIG	. T
SefA	SEF-14 fimbirae	AGFVGNKAV	T \
Caf1M Gi do	CaflM Gi donor sequence	138ICNNIAFQVFVGVD125	1

Fig. 11.